



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 28 July 2016 (#23)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa Coetsee cdevries@sun.ac.za) **as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date**. The NIH grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.**

Important notices

- National Institute of Neurological Disorders and Stroke (NINDS) Policy for Submission of Applications Containing Clinical Trials ([NOT-NS-16-034](#))
- Notice of Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Participation in PAR-16-262 "Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01)" ([NOT-HD-16-022](#))

1. Revolutionizing Innovative, Visionary Environmental health Research (RIVER)

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [RFA-ES-16-008](#)

Type: R35

Application Due Date: October 24, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: National Institute of Environmental Health Sciences (NIEHS) Revolutionizing Innovative, Visionary Environmental health Research (RIVER) program seeks to provide support for the majority of the independent research program for outstanding investigators in the Environmental Health Sciences, giving them intellectual and administrative freedom, as well as sustained support to pursue their research in novel directions in order to achieve greater impacts. The program seeks to identify individuals, regardless of career stage, with a track record of innovative and impactful research and combine their existing investigator-initiated research into a single seven year award with direct costs of up to \$750,000 based on current NIEHS funding.

Budget: NIEHS intends to commit \$5 M in FY 2017 to fund 4-5 awards. Application budgets are limited to the combined total Direct Costs of NIEHS funded projects to be consolidated into the R35 award as outlined above, plus 10%, not to exceed a total direct costs of \$750,000 annually. The budget requested needs to reflect the actual needs of the proposed project. Applicants may request up to 8 years of support, which must be justified within the actual needs of the proposed research program.

2. Assay Development and Screening to Discover Therapeutic or Imaging Agents for Diseases of Interest to the NIDDK

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [PA-16-374](#)

Type: R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The goal of this Funding Opportunity Announcement (FOA) is to develop, validate, or conduct a screen using a novel assay to identify therapeutic or imaging agents relevant to health related outcomes of interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). It is expected that state of the art measures of basic cellular processes or molecular events that are key mediators of disease pathogenesis are incorporated into these novel assays. Such assays should be useable in screens for molecules that modulate or monitor these processes or events in an unbiased and efficient manner. In particular, the NIDDK is interested in assays utilizing phenotypic readouts that provide opportunities to measure disease-relevant endpoints and lay the groundwork for future therapeutic and imaging agent discovery and development programs. It is expected that there is significant novelty in the assay approach to be developed or library to be screened and that this is articulated clearly in the application. It is not intended to support research focused on understanding normal biology, disease processes, or performing later-stage optimization of therapeutic or imaging agents. At the end of the project period, a successful project will have either 1) developed and validated a novel assay suitable for identifying prototype therapeutic or imaging agents or 2) utilized a novel assay to identify prototype therapeutic or imaging agents.

Budget: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

D71 - International Research Training Planning Grant: To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

D43 - International Research Training Grants: To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R01 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

R35 - Outstanding Investigator Award: To provide long term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U19 - Research Program-Cooperative Agreements: supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

Glossary of selected acronyms:

- FOA** Funding Opportunity Announcement
- PA** Program Announcements (*click on “PA” to search for further funding opportunities*)
- RFA** Request for Applications (*click on “RFA” to search for further funding opportunities*)

Complete [Glossary and acronym list of NIH Terms](#)